이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
SMS Pharmaceuticals 관리
관리 기준 확인 2/4
SMS Pharmaceuticals' CEO는 Ramesh Potluri, Aug1990 에 임명되었습니다 의 임기는 34.08 년입니다. 총 연간 보상은 ₹ 30.75M, 97.6% 로 구성됩니다. 97.6% 급여 및 2.4% 보너스(회사 주식 및 옵션 포함). 는 ₹ 10.39B 가치에 해당하는 회사 주식의 36.22% 직접 소유합니다. 10.39B. 경영진과 이사회의 평균 재임 기간은 각각 5.3 년과 2.2 년입니다.
주요 정보
Ramesh Potluri
최고 경영자
₹36.9m
총 보상
| CEO 급여 비율 | 81.4% |
| CEO 임기 | 34.1yrs |
| CEO 소유권 | 36.2% |
| 경영진 평균 재임 기간 | 5.3yrs |
| 이사회 평균 재임 기간 | 2.2yrs |
최근 관리 업데이트
SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24
Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23Recent updates
SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Sep 07SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be Increased To ₹0.40
Aug 22Earnings Not Telling The Story For SMS Pharmaceuticals Limited (NSE:SMSPHARMA) After Shares Rise 27%
Aug 20SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Aug 08What SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 27% Share Price Gain Is Not Telling You
Jul 04Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Can Manage Its Debt Responsibly
Jun 21SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 25% Share Price Surge Not Quite Adding Up
Feb 29SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be ₹0.30
Sep 11SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 28SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet
Jun 07Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23SMS Pharmaceuticals (NSE:SMSPHARMA) Is Due To Pay A Dividend Of ₹0.30
Sep 15SMS Pharmaceuticals (NSE:SMSPHARMA) Will Pay A Dividend Of ₹0.30
Sep 01SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 18We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt
Mar 22SMS Pharmaceuticals' (NSE:SMSPHARMA) Earnings Are Of Questionable Quality
Jun 03Should You Be Adding SMS Pharmaceuticals (NSE:SMSPHARMA) To Your Watchlist Today?
Mar 08What Type Of Shareholders Make Up SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Registry?
Feb 22The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 185% And Shareholders Are Boasting About It
Feb 08SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 18
Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Meaningful Debt Burden
Dec 09Should You Take Comfort From Insider Transactions At SMS Pharmaceuticals Limited (NSE:SMSPHARMA)?
Nov 18CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | ₹570m |
| Mar 31 2024 | ₹37m | ₹30m | ₹498m |
| Dec 31 2023 | n/a | n/a | ₹361m |
| Sep 30 2023 | n/a | n/a | ₹288m |
| Jun 30 2023 | n/a | n/a | ₹150m |
| Mar 31 2023 | ₹31m | ₹30m | -₹71m |
| Dec 31 2022 | n/a | n/a | -₹42m |
| Sep 30 2022 | n/a | n/a | ₹9m |
| Jun 30 2022 | n/a | n/a | ₹259m |
| Mar 31 2022 | ₹38m | ₹26m | ₹622m |
| Dec 31 2021 | n/a | n/a | ₹789m |
| Sep 30 2021 | n/a | n/a | ₹911m |
| Jun 30 2021 | n/a | n/a | ₹791m |
| Mar 31 2021 | ₹47m | ₹21m | ₹625m |
| Dec 31 2020 | n/a | n/a | ₹458m |
| Sep 30 2020 | n/a | n/a | ₹319m |
| Jun 30 2020 | n/a | n/a | ₹308m |
| Mar 31 2020 | ₹26m | ₹20m | ₹316m |
| Dec 31 2019 | n/a | n/a | ₹386m |
| Sep 30 2019 | n/a | n/a | ₹405m |
| Jun 30 2019 | n/a | n/a | ₹406m |
| Mar 31 2019 | ₹32m | ₹20m | ₹400m |
| Mar 31 2018 | ₹32m | ₹20m | ₹317m |
보상 대 시장: Ramesh 의 총 보상 ($USD 368.39K )은 Indian 시장( $USD 184.76K ).
보상과 수익: Ramesh 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Ramesh Potluri (66 yo)
34.1yrs
테뉴어
₹36,875,000
보상
Mr. Ramesh Babu Potluri has been the Chairman and Managing Director of SMS Pharmaceuticals Limited since August 30, 1990. Mr. Potluri has pioneered the vision of developing SMS in to one of the leading Pha...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman & MD | 34.1yrs | ₹36.88m | 36.22% ₹ 10.8b | |
| Chief Financial Officer | 7yrs | ₹2.37m | 데이터 없음 | |
| Company Secretary & Compliance Officer | 2.6yrs | ₹1.53m | 데이터 없음 | |
| Executive Director | 3.7yrs | ₹36.83m | 15.74% ₹ 4.7b | |
| Assistant General Manager of HR and Legal | no data | 데이터 없음 | 데이터 없음 | |
| Head of HRD and General Manager of Purchases | no data | 데이터 없음 | 데이터 없음 |
5.3yrs
평균 재임 기간
61yo
평균 연령
경험이 풍부한 관리: SMSPHARMA 의 관리팀은 노련하고 경험 (평균 재직 기간 5.1 년)입니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman & MD | 34.1yrs | ₹36.88m | 36.22% ₹ 10.8b | |
| Executive Director | 4.3yrs | ₹36.83m | 15.74% ₹ 4.7b | |
| Additional Non-Executive Non-Independent Director | less than a year | 데이터 없음 | 2.58% ₹ 767.6m | |
| Non-Executive & Independent Director | 5.1yrs | ₹245.00k | 데이터 없음 | |
| Non-Executive & Independent Director | 6.3yrs | ₹590.00k | 0.035% ₹ 10.5m | |
| Additional Non-Executive Independent Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Non-Executive Non-Independent Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Non-Executive Independent Director | less than a year | 데이터 없음 | 데이터 없음 |
2.2yrs
평균 재임 기간
62yo
평균 연령
경험이 풍부한 이사회: SMSPHARMA 의 이사회는 경험(평균 재직 기간 2.1 년)으로 간주되지 않으므로 새 이사회가 필요합니다.